The following studies led by BC Children's Hospital and BC Women's Hospital researchers aim to improve diagnostics, as well as better understand the transmission of COVID-19 and the impact of genetics on risk factors. 

Click on the study titles below for more information. 

Proteome and metabolome modulation in COVID-19 patients

Philipp Lange, Principal Investigator

The goal of this study is to characterize the changes in the protein and metabolite composition of human cells and body fluids in response to an active or resolved infection with SARS-CoV-2 virus and its impact on the cellular physiology.

Contact: Brenda Tse

The SPRING Study: Severe acute resPiratory syndrome-Related coronavirus 2 prevalence In children and youNG adults in British Columbia: an observational study

Manish Sadarangani, Principal Investigator

Researchers at the Vaccine Evaluation Center would like to find out how many children and young adults in BC may have been infected with SARS-CoV-2 (the virus that was identified in December 2019 which causes the infectious disease known as COVID-19). The World Health Organization declared COVID-19 as a pandemic due to the rapid increase in the number of cases globally. Many cases in children, as well as in adults, have been mildly symptomatic or asymptomatic (without symptoms). This study will help researchers better understand the rates of COVID-19 infection amongst children and youth in BC, which are currently unknown. This valuable information can help to guide policies and recommendations in BC for both work and school environment.

For more information: The Vaccine Evaluation Center

Contact: Helen He

Smart Triage: Saving young lives — Triage and management of sepsis in children using the point-of-care Paediatric Rapid Sepsis Trigger (PRST) tool

Mark Ansermino, Principal Investigator

Our original goal was to develop and validate a prediction model and to perform clinical validation of a digital trigger tool to guide triage and treatment of children at health facilities in LMICs with suspected sepsis. COVID-19 is an example of one of the organisms that has the potential to cause sepsis.

Contact: Mark Ansermino

Secondary Household Attack Rate Evaluation of COVID-19 (SHARE-COVID)

Manish Sadarangani, Principal Investigator

The purpose of this study is to develop a better understanding of how COVID-19 infection spreads between people who live in the same household, including young children and household members who appear to be asymptomatic. We also hope to discover if there are biological differences between people who do become infected by someone else in the home, and people who do not become infected.

For more information: The Vaccine Evaluation Center

Contact: Brittany Seligman

COVID-19 Antibody Responses in Cystic Fibrosis Patients: (CAR-CF) Study

Mark Chilvers, Principal Investigator

Although there have been few cases in persons with Cystic Fibrosis (CF), the risk of Covid-19 in the CF population remains unknown.

It is important to know which CF patients do not have an antibody response to COVID-19 and are potentially susceptible to infection, thus requiring continued protective infection control practices. We also need to know whether Covid-19 infection leads to worsened pulmonary function in individuals with CF.

Contact: Alam Lakhani

COVID Sequencing: Host genetic factors underlying severe COVID-19

Catherine Biggs, Principal Investigator

This study will investigate why around five per cent of people with COVID-19 require critical care for severe disease (respiratory failure, hyperinflammatory response) while most experience minimal symptoms. We cannot identify who will develop severe disease, and the predisposing genetic factors are unknown.

We will combine next generation sequencing with functional characterization to achieve 2 objectives: 1) Genetics of COVID-19: determine what proportion of patients with severe COVID-19 have an underlying IEI and characterize the role of genetic factors in COVID-19 disease. 2) Targeted therapy: molecularly-targeted treatments (e.g., if patients with hyperinflammation have variants dysregulating JAK-STAT signaling, JAK inhibitors may be indicated).

Contact: Catherine Biggs